TNFRSF9 and neoplasm: In the C38 tumor model, the combination of domatinostat with an agonistic 4-1BB antibody doubled the tumor response rate over anti-4-1BB alone, further emphasizing the ability of domatinostat to increase the functional activity of CTLs.